These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29520401)

  • 1. N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies.
    Riedl CA; Hejl M; Klose MHM; Roller A; Jakupec MA; Kandioller W; Keppler BK
    Dalton Trans; 2018 Mar; 47(13):4625-4638. PubMed ID: 29520401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
    Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes.
    Lari M; Martínez-Alonso M; Busto N; Manzano BR; Rodríguez AM; Acuña MI; Domínguez F; Albasanz JL; Leal JM; Espino G; García B
    Inorg Chem; 2018 Nov; 57(22):14322-14336. PubMed ID: 30379535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
    Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
    Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties.
    Parveen S; Tong KKH; Khawar Rauf M; Kubanik M; Shaheen MA; Söhnel T; Jamieson SMF; Hanif M; Hartinger CG
    Chem Asian J; 2019 Apr; 14(8):1262-1270. PubMed ID: 30706633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
    Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A
    Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro antitumor activity of arene-ruthenium(II) curcuminoid complexes improves when decreasing curcumin polarity.
    Caruso F; Pettinari R; Rossi M; Monti E; Gariboldi MB; Marchetti F; Pettinari C; Caruso A; Ramani MV; Subbaraju GV
    J Inorg Biochem; 2016 Sep; 162():44-51. PubMed ID: 27293144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, characterization, and biological activity of cationic ruthenium-arene complexes with sulfur ligands.
    Zain Aldin M; Zaragoza G; Choquenet E; Blampain G; Berger G; Delaude L
    J Biol Inorg Chem; 2024 Jun; 29(4):441-454. PubMed ID: 38753160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Diimines as Versatile, Derivatizable Ligands in Ruthenium(II) p-Cymene Anticancer Complexes.
    Biancalana L; Batchelor LK; Funaioli T; Zacchini S; Bortoluzzi M; Pampaloni G; Dyson PJ; Marchetti F
    Inorg Chem; 2018 Jun; 57(11):6669-6685. PubMed ID: 29790340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
    Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
    Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
    Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
    Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
    Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET
    Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New π-arene ruthenium(II) piano-stool complexes with nitrogen ligands.
    Grau J; Noe V; Ciudad C; Prieto MJ; Font-Bardia M; Calvet T; Moreno V
    J Inorg Biochem; 2012 Apr; 109():72-81. PubMed ID: 22387934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.
    Zhao Z; Luo Z; Wu Q; Zheng W; Feng Y; Chen T
    Dalton Trans; 2014 Dec; 43(45):17017-28. PubMed ID: 25087850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
    Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
    Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introducing
    Harringer S; Wernitznig D; Gajic N; Diridl A; Wenisch D; Hejl M; Jakupec MA; Theiner S; Koellensperger G; Kandioller W; Keppler BK
    Dalton Trans; 2020 Nov; 49(44):15693-15711. PubMed ID: 33135027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.
    Fandzloch M; Dobrzańska L; Jędrzejewski T; Jezierska J; Wiśniewska J; Łakomska I
    J Biol Inorg Chem; 2020 Feb; 25(1):109-124. PubMed ID: 31741123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution equilibria of anticancer ruthenium(II)-(η(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity.
    Enyedy EA; Sija E; Jakusch T; Hartinger CG; Kandioller W; Keppler BK; Kiss T
    J Inorg Biochem; 2013 Oct; 127():161-8. PubMed ID: 23721887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.